 <h1>Intropin Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>dopamine</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about dopamine. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Intropin.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to dopamine: parenteral injection concentrate for iv infusion, parenteral injection for iv infusion</i></p><h3>Warning</h3><p><ul>
Extravasation Risk
<li>
<i>Phentolamine</i> is the local antidote for peripheral ischemia resulting from extravasation of dopamine.&lt;sup&gt;115&lt;/sup&gt; &lt;sup&gt;116&lt;/sup&gt;</li></ul></p><ul>
Extravasation Risk
<li>
<i>Phentolamine</i> is the local antidote for peripheral ischemia resulting from extravasation of dopamine.&lt;sup&gt;115&lt;/sup&gt; &lt;sup&gt;116&lt;/sup&gt;</li></ul><p>
<li>
<i>Phentolamine should be given as soon as possible</i> after extravasation is noted.&lt;sup&gt;115&lt;/sup&gt; &lt;sup&gt;116&lt;/sup&gt;</li></p><p>
<li>
Infiltrate the affected area (using a syringe with a fine hypodermic needle) liberally throughout as soon as possible with 10–15 mL of 0.9% sodium chloride injection containing 5–10 mg of phentolamine mesylate (an α-adrenergic blocking agent) to prevent sloughing and necrosis in ischemic areas.&lt;sup&gt;115&lt;/sup&gt; &lt;sup&gt;116&lt;/sup&gt;</li></p><p>
<li>
In children, phentolamine mesylate doses of 0.1–0.2 mg/kg (maximum: 10 mg per dose) may be infiltrated.&lt;sup&gt;116&lt;/sup&gt;</li></p><p>
<li>
Sympathetic blockade with phentolamine causes immediate and conspicuous local hyperemic changes if the area is infiltrated within 12 hours.&lt;sup&gt;115&lt;/sup&gt; &lt;sup&gt;116&lt;/sup&gt;</li></p><p></p><p>Side effects include:</p><p>Dopamine (the active ingredient contained in Intropin) may cause cardiac conduction abnormalities (e.g., ventricular arrhythmia, atrial fibrillation, widened QRS complex, ectopic heartbeats), tachycardia, angina, palpitation, bradycardia, vasoconstriction, hypotension, hypertension, dyspnea, nausea, vomiting, headache, anxiety, azotemia, piloerection, and gangrene of the extremities. </p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to dopamine: intravenous solution</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Ectopic beats, tachycardia, anginal pain, palpitation, hypotension, vasoconstriction</p><p><b>Uncommon</b> (0.1% to 1%): Aberrant ventricular conduction/ventricular arrhythmia, bradycardia, widened QRS complex, hypertension</p><p><b>Frequency not reported</b>: Gangrene of the feet/extremities, peripheral cyanosis, fatal ventricular arrhythmias, atrial fibrillation, cardiac conduction abnormalities<sup>[Ref]</sup></p><p>Gangrene of the feet occurred in patients with preexisting vascular disorders and/or at doses of at least 10 to 14 mcg/kg/min given for prolonged periods of time.</p><p></p><p>Ventricular arrhythmias occurred at very high doses.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, vomiting<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Dyspnea<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very rare</b> (less than 0.01%): Gangrene</p><p><b>Frequency not reported</b>: Piloerection<sup>[Ref]</sup></p><h3>Local</h3><p><b>Frequency not reported</b>: Necrosis, tissue sloughing, local ischemia and vasoconstriction<sup>[Ref]</sup></p><p>Necrosis and tissue sloughing may be caused by extravasation of this drug.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Frequency not reported</b>: Anxiety<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Azotemia<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Mydriasis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Hypovolemia<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Intropin (dopamine)." DuPont Pharmaceuticals, Wilmington, DE. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Strattera vs Adderall: What is the difference?</li>
</ul><h2>More about Intropin (dopamine)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: catecholamines</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Nonobstructive Oliguria</li>
<li>Shock</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>